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Abstract
Garcinol, harvested from Garcinia indica, has traditionally been used in tropical regions and
appreciated for centuries; however its biological properties are only beginning to be elucidated.
There is ample data to suggest potent antioxidant properties of this compound which have been
used to explain most of its observed biological activities. However, emerging evidence suggests that
garcinol could be useful as an anti-cancer agent, and it is increasingly being realized that garcinol is
a pleiotropic agent capable of modulating key regulatory cell signaling pathways. Here we have
summarized the progress of our current research knowledge on garcinol and its observed
biological activities. We have also provided an explanation of observed properties based on its
chemical structure and provided an insight into the structure and properties of chalcones, the
precursors of garcinol. The available data is promising but more detailed investigations into the
various properties of this compound, particularly its anti-cancer activity are urgently needed, and
it is our hope that this review will stimulate further research for elucidating and appreciating the
value of this nature's wonder agent.
Introduction
It is difficult to imagine that the pink sweet smelling drink
that is served to the world travelers spending summer hol-
idays on the beautiful beaches of Goa in India, upon their
arrival at the hotel, could one day end up on the labora-
tory tables of Cancer Institutes around the world. The wel-
come drink happens to be made from the syrup
formulated from the fruits locally known as 'Kokum'
which is steeped in sugar syrup to make a drink which is
used to avoid skin damages and allergies from the sun and
tropical climate. The plant grows extensively on the west-
ern coast of India and is known by various names across
India including Bindin, Biran, Bhirand, Bhinda, Katambi,
Panarpuli, Ratamba or Amsool. In English language, it is
also known by various names such as Mangosteen, wild
Mangosteen, or Red Mango. According to botanical classi-
fication the tree is classified as Garcinia indica (Family:
Clusiaceae; Genus: Garcinia)which has many culinary,
pharmaceutical and industrial uses. The genus Garcinia
includes some 200 species found in the tropics, especially
Asia and Africa. Out of 35 species found in India, 17 are
endemic. Of these, seven are endemic to the region of
Western Ghats including the state of Goa, six in the Anda-
man and Nicobar Islands and four in the North-Eastern
region of India.
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The  Garcinia indica seed contains 23-26% oil, which
remains solid at room temperature and is used in the
preparation of chocolates, medicines and cosmetics. It is
used as a slightly bitter spice in recipes from the state of
Maharashtra in India and as a souring agent and a substi-
tute for tamarind paste in Indian curries. Recently, some
industries have started extracting hydroxycitric acid
(HCA) from the rind of the fruit which is an important
constituent used as a hypocholesterolaemic agent. HCA is
also a potential anti-obesity agent [1]. It suppresses fatty
acid synthesis, lipogenesis, and food intake, and thus
induces weight loss. Kokum Butter is an excellent emol-
lient used by the cosmetic industry for preparations of
lotions, creams, lip-balms and soaps. It has relatively high
melting point and is considered as one of the most stable
exotic butter which dose not need any refrigeration. It is
extracted from the Kokum seed and is supposed to reduce
degeneration of the skin cells and restore elasticity. The
extract of the plant finds place in the specialty cuisine of
West Coast of India as an appetizer while decoction of the
bark is used for treating paralysis. The antioxidant activity
of aqueous extract of the plant has been reported, which
is higher than other reported spices and fruits thus pro-
moting its use in cooking, home remedies and as a soft
drink [2]. Garcinia indica extract has also been shown to
inhibit  Aspergillus flavus and aflatoxin B1  production
thereby demonstrating its putative bio-preservative prop-
erties [3]. Addition of Garcinia extract to fresh skipjack
(dark muscle fish) has been demonstrated to prevent his-
tamine formation by lowering the pH to 3.2-3.6 [4]. Since
histamine is known to give rise to allergic reactions, Gar-
cinia extracts can potentially find use in anti-allergy med-
ications.
Isolation and characterization of chemical 
constituents
Garcinia indica extracts, especially from its rind, are rich in
polyisoprenylated benzophenone derivatives such as Gar-
cinol and its colorless isomer, Isogarcinol. The rind also
contains hydroxycitric acid (HCA), hydroxycitric acid lac-
tone, citric acid and oxalic acid. The structures of these
compounds are shown in Figure 1. The fruit also contains
other compounds including malic acid, polyphenols, car-
bohydrates, anthocyanin, pigments and ascorbic acid.
Garcinol shows strong antioxidant activity since it con-
tains both phenolic hydroxyl groups as well as a β-dike-
tone moiety, and in this respect it resembles with the well-
known antioxidant of plant origin, viz. Curcumin [5] (Fig-
ure 1).
A reverse-phase high-performance liquid chromato-
graphic method has been developed by Chattopadhyay
and Kumar for qualitative and quantitative analysis of
Xanthochymol and Isoxanthochymol in the fruit rinds,
leaves and seed pericarps of Garcinia indica using PDA
detector and electrospray ionization mass spectra.
Absorption at 276 nm was chosen as the measuring wave-
length at which resolution of both compounds could be
obtained [6-9]. More recently, these workers have devel-
oped a rapid, sensitive and simple reverse-phase high-per-
formance liquid chromatography-electrospray ionization
mass spectrometric method for the identification and
quantification of two isomeric polyisoprenylated benzo-
phenones, isoxanthochymol and camboginol, in the
extracts of the stem bark, seeds and seed pericarps of Gar-
cinia indica and in the fruit rinds of Garcinia cambogia [10].
The major organic acid in leaves and rinds of Garcinia
indica is reported to be (-)-hydroxycitric acid, present to
the extent of 4.1-4.6 and 10.3-12.7% respectively, as
determined by HPLC [11,12].
Garcinol, with a molecular weight of 602, is the active
principle of Garcinia indica, which is crystallized out as
yellow needles (1.5%) from the hexane extract of the fruit
rind. The molecular formula and the absorption spectral
data indicate that the compound is possibly related to the
isomeric Xanthochymol and more appropriately, in view
of the sign of optical rotation, to Cambogin. The presence
of an enolisable 1, 3-diketone system in the molecule is
confirmed by the formation of two isomeric trimethyl
ethers, hydrolysable to single dimethyl ether with dilute
alkali. Alkali degradation of the methyl ether under
stronger conditions (20% ethanolic KOH, reflux) yields
veratric acid indicating the presence of a 3,4-dihydroxy-
benzoyl unit. The UV spectrum of garcinol suggests that
the 1, 3-diketone system is conjugated to the 3, 4-dihy-
droxybenzoyl moiety. The IR spectrum of the trimethyl
ether shows the presence of a saturated carbonyl group
(1727 cm-1) and two α, β-unsaturated carbonyl groups
Structure of Garcinol, Curcumin and compounds extracted  from Garcinia indica Figure 1
Structure of Garcinol, Curcumin and compounds 
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(1668 and 1642 cm-1), accounting for all the oxygen
atoms.
The PMR spectrum of garcinol in CDC13 shows the pres-
ence of two saturated tertiary methyls (singlets at δ l.01
and 1.17) and seven = C-CH3 groups (signals at δ 1.54 for
two methyls and at 1.60, 1.67, 1.70, 1.74 and 1.84 for one
methyl each). It also shows signals for a vinylic methylene
(δ 4.38, 2 H, broad singlet) and three other olefinic pro-
tons (δ 5.0 m) in addition to three aromatic protons (ABX
pattern around δ 6.60 and 6.95) and a hydrogen bonded
phenolic hydroxyl at δ 18.0. The mass spectrum of garci-
nol is very similar to that of Xanthochymol exhibiting
major peaks at m/e 602(M+), 465(M+ -C10H17, base peak),
341 (465-C9H16) and 137 (Dihydroxybenzoyl). These fea-
tures clearly indicate that the structure of garcinol is bio-
genetically derivable from Maclurin (2,4,6,3',4'-
pentahydroxybenzophenone) and five isoprenyl units
[13,14].
Chemistry of garcinol
The principle antioxidant substance of Garcinia indica and
other species is Garcinol (Figure 1) also called as Cam-
boginol, which is a tri-isoprenylated chalcone [15,16].
This compound is extracted from the dried fruit rind of
the plant. It scavenges 1, 1-diphenyl-2-picrylhydrazyl
(DPPH) free radical (3 times more effectively than DL-R-
tocopherol), hydroxyl radical (more effectively than DL-
R-tocopherol), methyl radical, and superoxide anion [17].
Sang et al. have reported the structure of some oxidation
products of garcinol and have proposed mechanisms for
the formation of these products [18,19]. Their results sug-
gest that garcinol can play an important role in the treat-
ment of gastric ulcers caused by the hydroxyl radicals or
chronic infection with Helicobacter pylori, which, together
with cells from gastric mucous membrane, produces
hydroxyl radicals and superoxide anions. Presently, treat-
ment with Clarithromycin antibiotic is the therapy of
choice for treating H. pylori infection, which, however, suf-
fers from side effects and emergence of rapid resistance
[20,21]. Garcinol may be a viable alternative to conven-
tional antibiotics. Garcinol shows antibacterial activity
against Methicillin-resistant Staphylococcus aureus [22]
which is comparable to that of the antibiotic Vancomycin
(MIC - 3-12 μg/mL for garcinol Vs. 6 μg/mL for Vancomy-
cin) [23]. It also inhibits topoisomerases I and II (IC50 =
43 and 55 μg/mL respectively) at concentrations compa-
rable to that of Etoposide (IC50 = 70 μg/mL for topoi-
somerases II) [24]. Although this compound has been
shown to exhibit therapeutic activity against gram-posi-
tive and gram-negative cocci, mycobacteria and fungi, it
has been found to be inactive against gram-negative
enteric bacilli, yeasts and viruses [25]. Garcinol exerts
anti-cholinesterase properties towards acetyl cholineste-
rase (AChE) and butylcholinesterase. The IC50 value of
garcinol (0.66 μM) against AChE is comparable to that of
the reference compound Galanthamine (0.50 μM) [26].
Isogarcinol also shows biological activities similar to that
of garcinol and has been claimed to be an anti-inflamma-
tory and antitumor compound, a lipase inhibitor, an anti-
obesity agent as well as an antiulcer agent [18]. Sang et al.
have studied the interaction of garcinol with peroxyl rad-
icals generated by thermolysis of the initiator 2, 2'-azobis-
isobutyronitrile (AIBN) and have succeeded in isolating
and characterizing reaction products of garcinol in a
homogeneous acetone system. The resulting compounds
were found capable of inducing apoptosis in human
leukemia HL-60 cells and inhibit NO radical generation as
well as LPS-induced iNOS gene expression, respectively
[18,19]. Garcinol showed good antitumor activity against
human leukemia HL-60 cells, being more effective than
curcumin, which was used as a reference compounds in
these studies. In addition to HL-60 cells, the chemothera-
peutic potential of garcinol has been examined on other
cell lines as well such as murine macrophage RAW 264.7
cells and cyclin D1-positive cells showing similar results.
Additionally garcinol also inhibits histone acetyltrans-
ferases (HATs, IC50 = 7 μM) and p300/CPB-associated fac-
tor (PCAF, IC50 = 5 μM), both of which are known to
modulate gene expression [27].
Biological activities of garcinol
a. Antioxidant Activity
Garcinol has been shown to possess antioxidant activity
in the H2O2-NaOH-DMSO system as well as the radical
scavenging activity against superoxide anion, hydroxyl
radical and methyl radical respectively. The emulsified
garcinol suppresses superoxide anion to almost same
extent as DL-α tocopherol by weight, while it exhibits
nearly three times greater free radical scavenging activity
against 2, 2, diphenyl-1-picrylhydrazyl (DPPH) radicals
than DL-α tocopherol by weight [28]. The following par-
agraphs describe the known mechanism of antioxidant
activity of garcinol.
Hong  et al. have investigated possible mechanisms of
antioxidant action of garcinol and its derivatives on ara-
chidonic acid metabolism and NO radical synthesis at
concentrations (>1 μM) that may be achievable under in
vivo conditions. The preliminary results indicate that peak
plasma and urine plasma concentration levels of garcinol
in CD-1 female mice were 12 and 2.7 μM respectively,
after oral gavage of garcinol (10 mg dose per mouse) [29].
Sang et al. also proposed the antioxidant mechanism of
garcinol according to which the compound reacts with
peroxyl radicals by a single electron transfer followed by
deprotonation of the hydroxyl group from the enolized 1,Journal of Hematology & Oncology 2009, 2:38 http://www.jhoonline.org/content/2/1/38
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3-diketone to form a resonance pair. Depending on the
position of hydroxyl group (C-3 or C-5) which initiates
the reaction, different compounds are formed [18,19].
The neuroprotective effects of garcinol were examined by
Liao et al who found that at 5 μM concentration it pre-
vented NO radical accumulation in LPS-treated astrocytes
and significantly reduced the expression of LPS-induced
inflammatory mediators, such as iNOS and COX-2 [30].
These results suggest that the neuroprotective effects of
garcinol are associated with its antioxidant nature involv-
ing inhibition of iNOS induction in astrocytes. It has been
suggested that the compound may be neuroprotective
against brain injury through similar mechanism [30].
Yamaguchi et al. studied various pharmacological activi-
ties of garcinol including antioxidant activity, chelating
activity, free radical scavenging activity and anti-glycation
activity. They observed that garcinol exhibited reasonable
antioxidant activity in the micellar linoleic acid peroxida-
tion system and exhibited chelating activity at almost the
same level as citrates. In a phenazine methosulfate/
NADH-nitro blue tetrazolium system garcinol exhibited
superoxide anion scavenging activity and suppressed pro-
tein glycation in a bovine serum albumin/fructose system.
Thus, the compound may be useful as a glycation inhibi-
tor under specified conditions [17].
b. Anti-inflammatory activity
Aberrant arachidonic acid metabolism and generation of
nitric oxide radicals (NO) have been shown to be
involved in inflammation and carcinogenesis [29]. Ara-
chidonic acid is released by phospholipase A2 (cPLA2)
from membrane phospholipids and is further metabo-
lized by cyclooxygenase (COX), lipooxygenase (LOX)
enzymes and Cytochrome P450 pathways. Modulation of
arachidonic acid metabolism by inhibiting COX and LOX
enzymes has been considered as an effective approach for
treating inflammation and for cancer chemoprevention
[29]. Garcinol and its derivatives modulate arachidonic
acid metabolism by retarding the phosphorylation of
cytosolic PLA2 (cPLA2) through the inhibition of extracel-
lular ERK1/2 kinase activation and suppression of iNOS
expression through modulation of the Janus kinase (JAK)/
STAT-1 signaling pathway. When added prior to LPS, gar-
cinol suppressed NF-κB activation and COX-2 expression
through the interruption of LPS binding to toll-like recep-
tors [29].
The nitric oxide radical moiety is involved in various phys-
iological processes, including vasodilation, inhibition of
platelet function, synaptic neurotransmission as well as
host defense. The formation of NO radicals from arginine
in the biological system is catalyzed by three different
types of nitric oxide synthase (NOS) enzymes, viz.
endothelial NOS, neuronal NOS and inducible NOS
(iNOS), respectively. The enzyme iNOS is stimulated by
inflammatory cytokines for NO production by macro-
phages and by many other cell types. It has been reported
that garcinol inhibits the expression of iNOS and COX-2
in lipopolysaccharide (LPS)-activated macrophages [31].
It was observed that garcinol strongly blocks the LPS-
induced activation of eukaryotic transcription factor NF-
κB [31]. This inhibition of NF-κB activation takes place
through the suppression of phosphorylation of IκB-α and
p38 Mitogen-Activated Protein Kinases (MAPK). Garcinol
lowers the LPS-induced increase of intracellular reactive
oxygen species (ROS), which contribute to the activation
of NF-κB [31].
Recently Koeberle et al. have shown that garcinol signifi-
cantly interferes with two enzymes that play crucial roles
in inflammation and tumorigenesis, viz. 5-lipoxygenase
and microsomal prostaglandin PGE2 synthase (mPGES)-1
[32]. In cell-free assays garcinol inhibits the activity of
purified 5-lipoxygenase and blocks the mPGES-1-medi-
ated conversion of PGH2 to PGE2 with IC50 values of 0.1
and 0.3 μM respectively. Garcinol was found to suppress
5-lipoxygenase product formations in intact human neu-
trophils and reduced PGE2 formation in interleukin-1β-
stimulated A549 human lung carcinoma cells as well as in
human whole blood stimulated by lipopolysaccharide.
Garcinol also interfered with isolated COX-1 enzyme
(IC50 = 12 μM) and with the formation of COX-1-derived
12(S)-hydroxy-5-cis-8, 10-trans-heptadecatrienoic acid as
well as thromboxane B2 in human platelets. The high
potency of garcinol in selectively suppressing PGE2 syn-
thesis and 5-lipoxygenase product formations provides
the molecular basis for its anti-inflammatory and anti-car-
cinogenic effects and rationalizes its therapeutic use [32].
c. Anticancer activity
The effects of garcinol and its oxidative derivatives have
been investigated on the growth of HT-29 and HCT-116
colon cancer cells, as well as IEC-6 and INT-407 which are
the normal immortalized intestinal cells [33]. Garcinol
and its derivatives showed potent growth-inhibitory
effects on all intestinal cells, with IC50 values in the range
of 3.2-21.4 μM after 72 hr treatment. Garcinol was found
to be more effective in inhibiting growth of cancer cells
than that of normal immortalized cells. These results indi-
cate that garcinol and its derivatives can inhibit intestinal
cancer cell growth without affecting normal cells. How-
ever, it should be pointed out that at low concentrations
garcinol can stimulate cell growth [33]. An earlier study
investigated the modifying effects of dietary feeding of the
compound on the development of azoxymethane
(AOM)-induced colonic aberrant crypt foci (ACF) in male
F344 rats [34]. The study also assessed the effects of garci-
nol on proliferating cell nuclear antigen (PCNA) index in
ACF and activities of detoxifying enzymes such as glutath-Journal of Hematology & Oncology 2009, 2:38 http://www.jhoonline.org/content/2/1/38
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ione S-transferase (GST) and quinone reductase (QR) in
liver. It was observed that garcinol administration signifi-
cantly lowers PCNA index in ACF and significantly ele-
vates liver GST and QR activities. In addition, garcinol was
also found to suppress O(2)(-) and NO generation and
expression of iNOS and COX-2 proteins. These observa-
tions suggest possible chemopreventive role of garcinol
[34]. In yet another report on the suppression of ACF for-
mation in rats by garcinol [35], the beneficial effects of
garcinol against tumor prevention in human colorectal
cancer cell line, HT-29 were investigated. Matrigel analysis
showed that exposure of HT-29 cells to 10 μM garcinol
inhibited cell invasion and decreased the dose-dependent
tyrosine phosphorylation of focal adhesion kinase (FAK).
Western blot analysis demonstrated that garcinol inhibits
activation of the Src, MAPK/ERK, and PI3K/Akt signaling
pathways. Additionally, these studies demonstrated that
decreased MMP-7 protein levels in HT-29 cells result in
sensitization to garcinol and that the compound signifi-
cantly inhibits the expression of MMP-7 in IL-1beta-
induced HT-29 cells. Thus, garcinol reduces cell invasion
and survival through the inhibition of FAK's downstream
signaling [35].
In human leukemia HL-60 cells, garcinol has been
reported to display strong growth inhibitory activity (IC50
= 9.42 μM) through induction of caspase-3/CPP32 activ-
ity in a dose- and time-dependent manner and inducing
degradation of poly (ADP-ribose) polymerase (PARP)
protein [5]. This induction of apoptosis provides a pivotal
mechanism for its cancer chemopreventive action. In a
study comprising four human leukemia cells lines, loss of
mitochondrial membrane potential was observed during
garcinol-induced apoptosis [36]. Garcinol also modulates
arachidonic acid metabolism by blocking the phosphor-
ylation of cPLA2 and by decreasing iNOS protein level
mediated via inhibition of STAT-1 activation. These activ-
ities may contribute to the anti-inflammatory and anti-
cancer properties of garcinol and its derivatives [29].
Two new benzophenones corresponding to the 13-O-
methyl ethers of garcinol and isogarcinol were tested for
their inhibitory effects on Epstein-Barr virus early antigen
activation induced by 12-O-tetradecanoylphorbol-13-ace-
tate (TPA) in Raji cells and their radical-scavenging ability
against 1,1-diphenyl-2-picrylhydrazyl (DPPH) was dem-
onstrated [37]. The cyclized polyprenylbenzophenones
showed comparable or stronger potential cancer chemo-
preventive activity when compared to glycyrrhetic acid, a
known anti-tumor promoter. Yoshida and coworkers
have demonstrated that dietary garcinol significantly
decreases the incidence and multiplicity of 4-NQO-
induced tongue neoplasms and pre-neoplasms as com-
pared to the control diet [38]. It also significantly reduced
the BrdU-labeling index and cyclin D1-positive cell ratio,
suggesting reduction in cell proliferation activity in the
tongue. The COX-2 expression in the tongue lesions was
also suppressed. They concluded that dietary administra-
tion of garcinol inhibits 4-NQO-induced tongue carcino-
genesis through suppression of increased cell
proliferation activity in the target tissues and/or COX-2
expression in the tongue lesions [38].
The potent cytotoxic activity for the methanol extract of
the fruit rinds of Garcinia indica against three human can-
cer cell lines, viz. colon (COLO-320-DM), breast (MCF-7)
and liver (WRL-68) has been reported [39]. Fractionation
of the methanol extract into hexane-, chloroform- and
ethyl acetate-soluble portions was performed and their
cytotoxic activity was evaluated. The ethyl acetate fraction
was found to be the most effective as compared to the two
other fractions. Thus, current results provide evidence for
the potential of garcinol as a chemopreventive agent in
carcinogenesis. Additionally, feeding garcinol-containing
diets does not cause retardation of body weight gain and
pathological alterations in liver and other organs includ-
ing kidney, lung, heart, and esophagus, which is indica-
tive of the low toxicity of the compound, which is a very
attractive feature of any anti-cancer agent.
d. Anti-HIV Activity
Histone acetylation is a diagnostic feature of transcrip-
tionally active genes [40]. The proper recruitment and
function of histone acetyltransferases (HATs) and histone
deacetylases (HDACs) are key regulatory steps for gene
expression and cell cycle. Functional defects of either of
these enzymes may lead to several diseases, including can-
cer. It has been reported that garcinol is a potent non-spe-
cific inhibitor of histone acetyltransferases p300 (IC50 =
7 μM) which strongly inhibited HAT activity-dependent
chromatin transcription, whereas transcription from DNA
template was not affected [40]. In order to find out more
potent, specific, and less toxic inhibitors, Mantelingu et al.
[41] synthesized and characterized several derivatives of
isogarcinol (IG), a product of intramolecular cyclization
of garcinol, by controlled modification and mono-substi-
tution at C-14 position. In this way they were able to syn-
thesize 14-isopropoxy IG (LTK-13) and 14-methoxy IG
(LTK-14) derivatives of isogarcinol. The di-substitution
yielded 13, 14 di-isopropoxy IG (LTK-13A), 13, 14 di-
methoxy IG (LTK-14A), 13, 14 di-acetoxy IG (LTK-15) and
13, 14 di-sulfoxy (LTK-19) isogarcinol compounds,
respectively. It was found that the mono-substituted isog-
arcinol derivatives like LTK-13, -14, and di-substituted
LTK-19 derivative could inhibit the p300-HAT activity but
not the PCAF-HAT activity, although the parent isogarci-
nol compound inhibited HAT activities of both p300 and
PCAF non-specifically.Journal of Hematology & Oncology 2009, 2:38 http://www.jhoonline.org/content/2/1/38
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Interestingly, one of the derivatives, LTK-15, seemed to
loose the HAT inhibition activity: it could inhibit the
p300-mediated acetylation less than 10% and had no
effect on PCAF-HAT activity. Furthermore, the other di-
substituted isogarcinol derivatives, LTK-13A and LTK-
14A, also lost their activity completely. The IC50 values, of
LTK-13, -14, and -19, to inhibit p300- HAT activity were
found to be 5-7 μM, which is comparable to isogarcinol.
In order to visualize the inhibition pattern of histone
acetylation, HAT assay products were analyzed by fluorog-
raphy followed by autoradiography. In agreement with
filter-binding data, it was found that in the presence of 10
μM of LTK-13, -14, and -19, the p300-mediated acetyla-
tion of histones H3 and H4 were equally inhibited up to
85%-90% as compared to DMSO solvent control. The his-
tone acetylation by PCAF (predominantly at histone H3)
was not affected by LTK-13, -14, and -19. As expected, the
presence of 10-μM concentration of isogarcinol efficiently
inhibited histone acetylation by both p300 and PCAF.
However, dose-dependent inhibition of p300- HAT activ-
ity was observed in the presence of LTK-14. Significantly,
HAT-activity of PCAF remained unchanged even in the
presence of 50 μM LTK14 and these chromatin modifying
enzyme activities were not affected by the presence of iso-
garcinol and its derivatives. Taken together, the data sug-
gests that the isogarcinol derivatives are specific inhibitors
of p300-HAT activity [41,42].
Since reversible acetylation of histone and non-histone
proteins plays pivotal role in cellular homeostasis [43],
dysfunction of histone acetyltransferases (HATs) is known
to cause several diseases including cancer, neurodegenara-
tion, asthma, diabetes, AIDS, and cardiac hypertrophy.
Moreover, since p300 protein plays a critical role in cell
growth, differentiation, and death, several of these func-
tions require intrinsic HAT activity of p300-HAT; how-
ever, the molecular basis of p300 contribution toward
diverse cellular processes is still unresolved [43]. Mante-
lingu et al. [41] have described the synthesis and charac-
terization of a set of p300-HAT-specific small-molecule
inhibitors derived from garcinol that are highly toxic to
cells. They have shown that these specific inhibitors selec-
tively block the p300-mediated acetylation of p53 in vivo.
Furthermore, inhibition of p300-HAT down-regulates
several genes but, significantly, few important genes are
also up regulated. Remarkably, these inhibitors were
found to be non-toxic to T cells, while inhibiting histone
acetylation of HIV infected cells and consequently inhib-
iting the multiplication of HIV. Hence, garcinol holds tre-
mendous therapeutic potential for different diseases
including AIDS and cancer.
e. Anti-ulcer activity
Garcinol has potent free radical scavenging activity as
judged from its interactions in three types of free radical
generating systems. Its scavenging activity against
hydroxyl radical has been found to be stronger than that
of α-Tocopherol [17] while its other scavenging activities
were found to be slightly weaker. Since hydroxyl radical is
regarded as the most damaging Reactive Oxygen Species
(ROS), garcinol is expected to be useful for preventing dis-
eases caused by the hydroxyl radical damages such as
stress-induced gastric ulcer [44,45] and NSAID drug-
induced gastric ulcers [46,47]. In the water immersion
stress model, Yamaguchi et al. have shown that garcinol
suppressed gastric injury formation to almost same extent
as cetraxate hydrochloride as a positive control [28]. It
also prevented indomethacin-induced gastric injury.
These results suggest that garcinol may have potential as
an anti-ulcer drug. Although mechanism of its anti-ulcer
activity is not yet understood, it may be speculated that
the compound may scavenge reactive oxygen species on
the surface of gastric mucosa, thus protecting cells from
injury [28].
Structure-activity considerations for garcinol
It has been clearly established that the C-3 kenotic group
and the phenolic ring bearing hydroxyl group are the prin-
cipal oxidation sites of garcinol generating its oxidized
products during metabolic transformations some of
which are also biologically active [18,19]. It has also been
found that the 1, 2 carbon-carbon double bond of the α,
β-unsaturated ketone is important for apoptosis-inducing
activity and cytotoxicity of garcinol [5]. The double bond
of the isoprenyl group is also a principal site of the anti-
oxidant reaction of garcinol; however, compounds with-
out having such substitution and bearing structural
resemblance to garcinol, like curcumin, have been found
to be potent antioxidants [48]. The isoprenyl chain of gar-
cinol consists of hydrophobic faces, which are important
for its binding to biological targets [49].
Chalcones as a garcinol analoges
Kostanecki, who pioneered work in the synthesis of natu-
ral coloring compounds, first coined the term 'chalcone'.
An interesting feature of chalcones is that they serve as
starting materials for another class of naturally occurring
and widely distributed pigments, flavones [50]. They are
considered to be precursors of flavonoids and isoflavo-
noids, which are abundant in edible plants. Chalcones are
intermediates in the synthesis of flavones. Chemically
they are open-chain flavonoids in which the two aromatic
rings are joined by a three-carbon α, β-unsaturated carbo-
nyl system (1, 3-diphenyl-2-propen-1-one). Chalcones
exhibit many pharmacological activities including anti-
leishmanial [51], anti-inflammatory [52,53], anti-mitotic
[54], anti-invasive [55], anti-tuberculosis [56], anti-fungal
[57], cysteinyl leukotriene receptor-1 antagonist [58],
anti-malarial [59,60], anti-plasmodial, antitumor, immu-
nosuppressive, antioxidant [61], anti-fibrogenic and
modulation of P-glycoprotein-mediated multi-drug resist-
ance [62]. Recent studies have shown that chalconesJournal of Hematology & Oncology 2009, 2:38 http://www.jhoonline.org/content/2/1/38
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inhibit cancer cell proliferation in vivo and are effective
agents against skin cancers [63,64]. They also induce
apoptosis in various cell types, including breast cancers
[65]. Several oxygenated chalcones; hydroxyl chalcones,
bis-chalcones and quinolinyl chalcone analogs exhibit
anti-malarial activity [66,67]. Some chalcones also dem-
onstrate their ability to block voltage-dependent potas-
sium channels [68]. These limited yet interesting studies
clearly suggest the beneficial effects of chalcones and
other derivatives in human health and diseases.
a. Structural chemistry of chalcones
Chalcones consist of two aromatic rings in trans configu-
ration, separated by three carbons, of which two are con-
nected by double bond while the third is a carbonyl group
[69]. Garcinol is an example of prenylated chalcones, con-
taining two aromatic rings separated by carbonyl group
(Figure 2), which is structurally similar to curcumin that
resembles chalcones when opened [5]. Genealogical stud-
ies have shown that chalcones have evolved prior to garci-
nol, and chalcones are derived from three acetates and
cinnamic acid as shown in Figure 2. Since chalcones are
efficient precursors of isoflavonoids, the required aryl
migration of ring B from the beta position to the alpha
position of the phenylpropanoid precursor must take
place after formation of the basic C15 skeleton [70]. A vast
number of naturally occurring chalcones are polyhydrox-
ylated in the aryl rings. The radical quenching properties
of the phenolic groups present in many chalcones have
raised interest in using these compounds as therapeutic
agents or food preservatives [71].
Chalcones are readily synthesized by the base-catalyzed
Claisen-Schimdt condensation of an aldehyde and appro-
priate ketone in a polar solvent like methanol or ethanol
(Figure 3) [61]. The synthesis of hydroxylated chalcones
by the Claisen-Schimdt method requires protection of the
phenolic hydroxyl groups on aldehyde and ketone (except
ortho-hydroxyl groups), generally as tetrahydropyranyl
(THP), methoxymethyl (MOM), or methoxyethoxyme-
thyl (MEM) ethers. The MOM and MEM ethers are cleaved
in the presence of acid, under such conditions; and hence
the side reactions compromise the yield of the final prod-
uct [72]. The Cα-Cβ double bond in the 'enone' moiety of
chalcones can adopt Z or E configuration. The E-isomer is
thermodynamically more stable and almost all chalcones
are isolated in this form. Iwata and co-workers have
reported isomerization of E-chalcone to the Z form by
exposing the methanolic solution of the chalcone to nor-
mal visible light [73]. Interestingly, the Z isomer showed
more potent antitumor activity than the original E form.
Photoisomerization of the predominant E isomer to the Z
isomer may cause change in biological activity and the
ease with which the reaction occurs suggest that it is pru-
dent to protect solution of chalcones from light.
Ducki et al. have noted that the two bonds were posi-
tioned cis with respect to each other in several X-ray crystal
structures of chalcones [54]. The s-cis conformer was more
stable than the s-trans conformer by, at least, 3.9 kJ/mol.
On the other hand, when a methyl group was introduced
at the Cα position, the disposition of the carbonyl and
Cα-Cβ double bonds altered to the trans orientation. For
these α-methyl chalcones, molecular mechanics calcula-
tions showed that the minimum energy conformers were
s-trans and no s-cis conformation was evident within a 10-
kJ/mol range of the global energy minimum. The α-
methyl group also caused significant loss of planarity
between ring A and the enone (θ1 56-88°). The α-methyl-
chalcones are found to have greater cytotoxic activity
against a human leukemia cell line than the unsubstanti-
ated analogues. Their unique geometrical features were
A. Structural similarity between chalcone and garcinol moie- ties Figure 2
A. Structural similarity between chalcone and garci-
nol moieties. B. Formation of chalcone and migration of 
ring B.
A. Scheme of synthesis of chalcones Figure 3
A. Scheme of synthesis of chalcones. B. s-cis and s-trans 
conformation of chalcones.Journal of Hematology & Oncology 2009, 2:38 http://www.jhoonline.org/content/2/1/38
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cited as a possible factor contributing to the enhanced
biological activity.
b. Biological Activities of chalcones
Xia and coworkers were the first to demonstrate improved
anti-proliferative activity of chalcones with substituted
amino groups [74]. LeBlanc et al. have shown that meth-
oxylated chalcones with a 3'-amino group had sub-micro-
molar IC50 values against murine melanoma B16 cells
[75]. Dimmock and coworkers proposed that the presence
of amino function increases the reactivity of chalcones as
Michael acceptors and subsequently their anti-prolifera-
tive activity [76]. They postulated that the amino function
would be protonated at low pH environment normally
encountered in tumors. The electron withdrawing effect of
the protonated ammonium function would enhance the
electrophilicity of the β-carbon in the enone linkage,
hence increasing its reactivity as a Michael acceptor [77].
Liquorice has been used in China for the treatment of gas-
tric and duodenal ulcers, bronchial asthma, Addison's dis-
ease, poisoning by food and drugs and skin disease such
as eczema and urticaria [78]. It still finds medicinal appli-
cation because of its wide-ranging therapeutic properties,
including relief from rheumatic and other types of pain
and healing effect on ulcers. The crude extract of Liquorice
has also found commercial use as a food additive in Japan
since it contains the sweetening principle glycyrrhizin.
The Liquorice extracts contains a chalcone, viz. Isoliqurit-
igenin, which is currently in use as a phosphodiesterase III
inhibitor for the treatment of cardiovascular diseases [79].
In the Far East countries such as Korea, Japan, and China,
another chalcone compound called 'Butein' has also been
traditionally used for treatment of pain, thrombotic dis-
ease, stomach cancer, and parasitic infection as well as a
food additive [80].
Anti-angiogenic effect of xanthochymol and Isoxantho-
chymol, the chalcones isolated from the hop, has been
reported [81]. A dose-dependant reduction of newly
formed capillary growth by xanthochymol was observed,
at a concentration range of 0.5-10 μM (IC50 value of 2.2
μM) under in vitro conditions. Later, it was shown that
xanthochymol repressed both the NF-κB and Akt path-
ways in the endothelial cells, indicating that components
of these pathways are major targets in the molecular
mechanism of this compound [82]. Xanthochymol also
reduced VEGF secretion, decreased cell invasion and met-
alloprotease production in acute and chronic myeloge-
nous leukemia cell lines [83]. 2'-hydroxychalcones,
4'hydroxychalcones and 2', 4'-dihydroxychalcones inhibit
12-Lipoxygenase and cyclooxygenase enzymes in the
mouse epidermis [84] and two synthetic 2'-hydroxychal-
cones that exert topical anti-inflammatory effects in mice
have also been reported [85]. The good selective inhibi-
tory effects of 2', 5' dihydroxychalcones on arachidonic
acid-induced platelet aggregation have been suggested
[86] and these reports, taken together, suggest that some
hydroxy chalcones might be promising antithrombotic or
anti-inflammatory agents.
Saxena and coworkers grafted chalcone derivatives on
estradiol framework some of which showed potent anti-
cancer activity against some human cancer cell lines [87].
Thus, compounds B and C in Figure 4 show potent activ-
ity against estrogen receptor-positive and hormone-
dependent human breast cancer cell lines, MCF-7. Chal-
cone  A  was further modified to yield corresponding
indanone derivative (C)  using the Nazarov reaction,
which showed better activity than the parent compound
against MCF-7 breast cancer cell line. Active anticancer
derivatives were also evaluated for osmotic hemolysis
using the erythrocyte as a model system. It was observed
that chalcone derivatives showing cytotoxicity against
cancer cell lines did not affect the fragility of erythrocytes
and hence may be considered as non-toxic to normal cells;
however, further research in this area is urgently needed.
Nitric oxide production by trimethoxy chalcone deriva-
tives, with various patterns of fluorination, has also been
evaluated [88]. One of this compounds, 2, 4, 6-trimeth-
oxy-20-trifluoromethylchalcone, inhibited the produc-
tion of NO and prostaglandin E2 in lipopolysaccharide-
stimulated RAW 264.7 macrophage cells. The inhibition
(76.3% inhibition at 10 μM concentration) was dose-
dependent without any evidence of a cytotoxic effect. It
was suggested that NO reduction was a consequence of
inhibition of the expression PGE2  accumulation. The
fluorinated chalcones tested by Nakamura et al. showed 5-
lipoxygenase inhibition on rat basophilic leukemia-1
(RBL-1) cells and inhibitory action on Fe3+-ADP induced
NADPH-dependent lipid peroxidation in rat liver micro-
somes [89]. The potencies were comparable or better than
those of the lead compound, viz. 3,4-dihydroxychalcone.
The structure of fluorinated chalcone is presented in Fig-
ure 5.
Why Chalcones are good analogs of Garcinol?
1. Structural Similarity
Chemically, garcinol is a polyisoprenylated chalcone con-
taining two aromatic rings separated by a carbonyl group.
The  α,β-unsaturated ketone system important for the
apoptosis-inducing activity is present between the two
rings in case of chalcones but within the ring B in case of
garcinol (Figure 2). Garcinol differs from chalcones with
the presence of isoprenyl groups, which makes its struc-
ture more complex and adds to its antioxidant activity [5].
2. Reaction Similarity
The reducibility of the carbonyl function in chalcones and
its relationship to biological activity has been investigated
[90]. In quantitative structure-activity relationships
(QSAR), the reducibility of the carbonyl function serves as
an indirect indicator of the electron density on the carbo-Journal of Hematology & Oncology 2009, 2:38 http://www.jhoonline.org/content/2/1/38
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nyl function. A readily reducible carbonyl group would
imply that the carbonyl carbon is electron-deficient. Elec-
tron delocalization along the α,  β-unsaturated chain
would render the β-carbon electron deficient and, accord-
ingly, more susceptible to attack by thiols and other nucle-
ophiles. Thus, one would expect a relationship between
the reducibility of the carbonyl bond (for example, meas-
ured in terms of reduction peak potentials in cyclic volt-
ametry) and the susceptibility to nucleophilic attack at the
β-carbon. On the other hand, in vivo reduction of the car-
bonyl group to an alcohol is unlikely to predominate, as
seen from the in vitro biotransformation of 4-dimethyl-
amino-4' (imidazol-1-yl) chalcone [91]. In case of garci-
nol no reactions has been reported but presence of
carbonyl group may suggest that such reactions could
occur.
3. Similarity in Biological Activities
Chalcones as well as garcinol are reported as potent anti-
oxidants and have been screened for their anti-inflamma-
tory, anti-cancer, anti-HIV, anti-biotic, anti-fungal and
anti-tumor activities. Structurally, chalcones are more eas-
ily amenable for structural modification and optimization
for some selective biological activity than garcinol.
4. Metal Complexation
The synthesis and structural studies of complexes of Co
(II), Ni (II), Cu (II), Zn (II) and Cd (II) with substituted
chalcones has been reported [92]. In general, for metal
Structures of some therapeutically active chalcone compounds Figure 4
Structures of some therapeutically active chalcone compounds.
Fluorinated chalcone: as anti-inflammatory agent Figure 5
Fluorinated chalcone: as anti-inflammatory agent.Journal of Hematology & Oncology 2009, 2:38 http://www.jhoonline.org/content/2/1/38
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complexation reactions, the Schiff derivatives of the chal-
cones are preferred which not only offer selectivity in
metal complexation reactions but also an enhancement in
biological activities. As yet no metal complexes of garcinol
have been reported.
Conclusions and perspectives
The chalcone garcinol is a potent antioxidant and anti-
cancer agent among its many other biological effects as
discussed above. Its structure makes it a very efficient scav-
enger of oxygen free radicals and an excellent inhibitor of
NO. Various biological activities of garcinol have been
reported (summarized in Table 1) and most of them relate
to its antioxidant nature. More recently, garcinol has gen-
erated considerable interest among cancer researchers,
and emerging data suggests its ability to protect against
chemically-induced carcinogenesis, as well as highlights
its potential use as a chemopreventive agent. An interest-
ing observation in this context is its ability to modulate
NF-κB, directly or indirectly [29,31]. Since NF-κB is
known to be a key player in the progression of human
cancers [93,94], its suppression by garcinol indicates a
putative potential molecular target of this compound,
which requires thorough testing for establishing the scien-
tific rationale for the use of garcinol as an anti-cancer
agent prior to its use as a novel therapeutic agent for the
treatment of human malignancies. Our preliminary
results (unpublished data) suggest an anti-cancer activity
of garcinol against human cancer cell lines through induc-
tion of apoptosis, and inhibition of NF-κB-DNA binding
activity.
Interestingly, induction of apoptosis by garcinol occurs
possibly through the activation of caspases as reported
[5,36], and our laboratory is beginning to conduct mech-
anistic studies in support of the role of garcinol as anti-
tumor agent against human malignancies, particularly in
view of the promising data that has emerged in recent
years. Another factor that is starting to generate interest
among researchers is the resemblance of the structure of
garcinol to that of curcumin (Figure 1). In a direct com-
parison between these two compounds, it was shown that
garcinol has better anti-tumor as well as apoptosis induc-
ing activity [5]. Moreover, garcinol has been shown to
Table 1: Summary of reported biological activities of garcinol
Activity Observations Reference
Anti-oxidant Efficient scavenging of free radicals Yamaguchi et al. [17]
Yamaguchi et al.[28]
Inhibition of NO and H2O2 production Sang et al. [18]
Inhibition of NO and iNOS Generation Sang et al. [19]
Inhibition of iNOS and COX-2 expression Liao et al. [31]
Inhibition of NO accumulation Liao et al. [30]
Anti-bacterial Activity against methicillin-resistant Staphylococcus aureus Iinuma et al. [23]
Rukachaisirikul et al. [22]
Efficient killing of Helicobacter pylori Chatterjee et al. [20]
Chatterjee et al. [21]
Anti-cancer Chemoprevention of colon tumorigenesis Tanaka et al. [34]
Induction of caspase-3-mediated apoptosis Pan et al. [5]
Loss of mitochondrial potential and activation of caspase-3 Matsumoto et al. [36]
Induction of apoptosis Balasubramanyam et al. [40]
Inhibition of tongue carcinogenesis Yoshida et al. [38]
Modulation of arachidonic acid metabolism and inhibition of STAT-1 Hong et al. [29]
Selective killing of colon cancer cells Hong et al. [33]
Induction of apoptosis and inhibition of cell invasion Liao et al. [35]Journal of Hematology & Oncology 2009, 2:38 http://www.jhoonline.org/content/2/1/38
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modulate various key signaling pathways, as discussed
above, which is consistent with the pleiotropic activity of
garcinol. In summary, the available literature on garcinol
points to its protective role against a number of human
ailments and diseases, particularly cancer; however,
detailed mechanistic studies are needed in order to fully
appreciate the potential beneficial effects of this com-
pound in human health and diseases.
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